aciclovir accord 25 mg/ml koncentrat do sporządzania roztworu do infuzji
accord healthcare polska sp. z o.o. - aciclovirum - koncentrat do sporządzania roztworu do infuzji - 25 mg/ml
lidocaini hydrochloridum noridem 10 mg/ml roztwór do wstrzykiwań
noridem enterprises ltd. - lidocaini hydrochloridum - roztwór do wstrzykiwań - 10 mg/ml
lidocaini hydrochloridum noridem 20 mg/ml roztwór do wstrzykiwań
noridem enterprises ltd. - lidocaini hydrochloridum - roztwór do wstrzykiwań - 20 mg/ml
dexaven 4 mg/ml roztwór do wstrzykiwań
bausch health ireland ltd. - dexamethasoni natrii phosphas - roztwór do wstrzykiwań - 4 mg/ml
micafungin zentiva 50 mg proszek do sporządzania koncentratu roztworu do infuzji
zentiva, k.s. - micafunginum - proszek do sporządzania koncentratu roztworu do infuzji - 50 mg
micafungin zentiva 100 mg proszek do sporządzania koncentratu roztworu do infuzji
zentiva, k.s. - micafunginum - proszek do sporządzania koncentratu roztworu do infuzji - 100 mg
kalydeco
vertex pharmaceuticals (ireland) limited - iwakaftor - zwłóknienie torbielowate - inne produkty układu oddechowego - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - zwłóknienie torbielowate - inne produkty układu oddechowego - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - zwłóknienie torbielowate - inne produkty układu oddechowego - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.